CA
NZ
UK
AU
IND
US
● Second-quarter net revenue was about $77.5 million, up about 22%, led by MACI.
Achieve Life Sciences (NASDAQ:ACHV) shares are indicated down 3.03% at $6.72 in premarket, after rising 5.96% to close at $6.93 on Tuesday. No company-specific catalyst was identified for the dip, and the healthcare sector ETF is also softer, down about 0.8%, as investors weigh …
Axogen (NASDAQ:AXGN) shares are indicated up 19.83% at $44.89 in premarket after third-quarter results topped expectations and management raised its 2026 outlook. Revenue of $75.8 million, up 26.2% from $60.1 million, beat the roughly $73.2 million consensus, and adjusted EPS of $0.21 beat the …
Boston Scientific (NYSE:BSX) shares are indicated down 6.08% at $42.32 in premarket after third-quarter results that were roughly in line but a cut to the 2026 outlook as the August cyberattack weighs on the business. Revenue of $5.14 billion was up 1.5%, and adjusted …
Cardiff Oncology (NASDAQ:CRDF) shares are indicated up 2.23% at $0.89 in premarket after the company appointed Leila Alland, MD, as interim Chief Medical Officer. She succeeds Roger Sidhu, MD, who stepped down. The stock closed Tuesday up 8.80% at $0.88.
Cellectis (NASDAQ:CLLS) shares are indicated up 5.71% at $1.11 in premarket after the company presented expanded preclinical data for .HEAL-101, its in vivo base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress. The stock closed …
Dyne Therapeutics (NASDAQ:DYN) shares are indicated down 4.19% at $16.23 in premarket after Oppenheimer downgraded the stock to Perform from Outperform and cut its price target to $15 from $40. Uncertainty around vHOT is the main focus for investors, even though the stock jumped …
GE HealthCare (NASDAQ:GEHC) shares are indicated up 7.09% at $76.15 in premarket after third-quarter results topped expectations and the company raised its 2026 outlook. Adjusted EPS of $1.34, up 25.1%, beat the $1.20 consensus, and revenue of $5.5 billion, up 7.2% with organic growth …
INVO Fertility (NASDAQ:IVF) shares are indicated up 1.12% at $0.62 in premarket after the company announced a 1-for-4 reverse split of its issued and outstanding and authorized common stock, effective October 30. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital …
Rapport Therapeutics (NASDAQ:RAPP) shares are indicated down 22.21% at $21.42 in premarket after the company priced underwritten offerings of its common stock and convertible notes. The common stock offering of about $200 million, including about $25 million of pre-funded warrants in lieu of shares, …
Please wait processing your request...